LARS Score baseline

TIMING TO MINIMALLY INVASIVE SURGERY AFTER NEOADJUVANT CHEMORADIOTHERAPY FOR RECTAL CANCER: A MULTICENTER RANDOMIZED CONTROLLED TRIAL

[crowdsignal type=”iframe” survey=”4F934F1FD1611B43″ height=”auto” domain=”igormonsellato” id=”lars-score-baseline”]